Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
Compugen Appoints David Silberman as Chief Financial Officer
Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024